Zhi-Gang Sun, Liang-Hui Zhao, Zhi-Na Li and Hai-Liang Zhu* Pages 1 - 12 ( 12 )
The treatment of cancer has always been a major problem in the world. Some cancers cannot be treated with surgery, but only with cancer drugs. Among many cancer drugs, small molecule inhibitors play an irreplaceable role. HER2 is one of the HER family, and the development of HER2 inhibitors has made a huge contribution to the treatment of cancer. Some HER2 inhibitors are already on the market, and some HER2 inhibitors are undergoing clinical research. The design, synthesis and development of new HER2 inhibitors targeting different targets are also ongoing, and some are even applying for clinical research. The HER2 inhibitors that are on the market have developed resistance, which brings great challenges to the HER2 inhibitor development in the future. This article reviews the development and challenges of HER2 inhibitors discovery.
Cancer, HER2, Challenges, Inhibitors, Drug resistance, Discovery
Central Laboratory, Linyi Central Hospital, No.17 Jiankang Road, Linyi 276400, Weifang Medical University, No.7166 Baotong West Street, Weifang 261000, Central Laboratory, Linyi Central Hospital, No.17 Jiankang Road, Linyi 276400, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, No.163 Xianlin Road, Nanjing 210023